Aardvark Therapeutics, Inc. (AARD)
Nasdaq · Healthcare · Biotechnology
$5.22+4.61%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $114M
- 52-week range
- $3.35 – $17.94
- 52-week change
- −71.34%
- EPS (trailing)
- −$3.21
- Analyst rating
- 2.3 Buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$57.6M
- Diluted EPS
- −$2.93
- Free cash flow
- −$54.3M
From the company’s annual report on SEC EDGAR.
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 28 employees · aardvarktherapeutics.com